SEC Comment Letter 0000000000-23-014019 to MIRA PHARMACEUTICALS, INC. (MIRA) (CIK 0001904286) (MIRA)
MIRA PHARMACEUTICALS, INC. (MIRA) (CIK 0001904286)
Date: Dec. 22, 2023 · CIK: 0001904286 · Accession: 0000000000-23-014019
AI Filing Summary & Sentiment
File numbers found in text: 333-276118
Letter
United States securities and exchange commission logo December 22, 2023 Erez Aminov Chief Executive Officer MIRA Pharmaceuticals, Inc. 855 N Wolfe Street, Suite 601 Baltimore, Maryland 21205 Re:MIRA Pharmaceuticals, Inc. Registration Statement on Form S-1 Filed December 18, 2023 File No. 333-276118 Dear Erez Aminov: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Alan Campbell at 202-551-4224 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Curt P. Creely
Show Raw Text
United States securities and exchange commission logo
December 22, 2023
Erez Aminov
Chief Executive Officer
MIRA Pharmaceuticals, Inc.
855 N Wolfe Street, Suite 601
Baltimore, Maryland 21205
Re:MIRA Pharmaceuticals, Inc.
Registration Statement on Form S-1
Filed December 18, 2023
File No. 333-276118
Dear Erez Aminov:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Alan Campbell at 202-551-4224 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Curt P. Creely